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INTRODUCTION
Although there are many models for animal testing, the
ideal model for chronic liver disease involving hepatic
encephalopathy has not been described yet. Different prob-
lems associated with the models have led researchers to
develop their own, sometimes unique experimental models,
which makes difficult the comparison between the results
of the conducted studies (1). Hepatic encephalopathy (HE)
definition, nomenclature, diagnosis and quantification con-
sensus were published in 2002 (2) where three types of HE
were considered: type A, associated with acute liver failure,
type B, associated with the existence of porto-systemic
communication (by-pass) without intrinsic liver disease
and type C, associated to liver cirrhosis. HE type C, in turn,
is classified according to their form of presentation as spon-
taneous or episodic HE, in relation to precipitating factors,
persistent HE is subdivided into mild (HE grade I), severe
(HE II-IV) or treatment-dependent (early developed after
abolition of treatment) and finally, the minimal HE, as the
first manifestation of HE. HE type C is the most common
form and from a clinical point of view, the episodic HE
type because of liver cirrhosis decompensation is the most
typical and relevant.
The ideal model of HE should reproduce most of the clin-
ical features of this syndrome in humans, as occurring mainly
in patients with chronic liver disease, being precipitated by
defined factors, it should be reversible with the correction of
precipitating factors and improved using rifaximin or ammo-
nia lowering-drugs, being strongly associated with altered
nitrogen metabolism and showing a wide spectrum of severity.
Because most patients with HE also suffer from chronic liver
disease, porto-systemic shunts, developed hyperammonemia
and systemic inflammation it is highly desirable that animal
models would include these facts (Fig. 1).
INDUCED CIRRHOSIS IN RATS BY CARBON
TETRACHLORIDE
This model is reasonably easy to reproduce, although a
significant number of animals die during CCl4 treatment,
especially if it is maintained until the onset of ascites. Mul-
tiple research groups have emphasized, moreover, that are
usually detected little change in behavior despite very
advanced and decompensated state of liver disease is
achieved. Although the well-compensated cirrhosis model
can only be useful to investigate the effects of hyperam-
monemia (HA) (3), which is usually moderate, it has been
shown that there is not a severe reduction of enzyme activity
of the urea cycle (4), which is commonly found in patients
with cirrhosis. For this reason, Snodgrass (4) stated that the
model was inappropriate for the study of chronic liver dis-
eases. It might be interesting to reproduce an advanced
stage of cirrhosis, but the presentation of severe ascites
complicates the interpretation of results regarding the ani-
mals’ behavior. Thus, currently, CCL4 model was not uti-
lized for HE research proposes any more. 
BILE DUCT LIGATION
Obstruction of the main bile duct induces a secondary bil-
iary cirrhosis, similar to that of humans, so it appears in ani-
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mals a secondarily liver failure, developing jaundice, portal
hypertension (5), porto-systemic shunt (6), bacterial translo-
cation and immune dysfunction (7). Bile duct-ligated rats do
not develop encephalopathy despite ammonia levels can be
increased (8), although these animals have shown a loss of
spontaneous motor activity (9) and memory deficits (10).
Multiple attempts were carry out to find a model using a bil-
iary ligation based technique –easy to perform– able to devel-
op episodes of unambiguous hepatic encephalopathy. In this
sense, a model was described in which encephalopathy was
manifested after a portacaval anastomosis in cirrhotic rats
by bile duct ligation, although this model was not widely
distributed, probably because of the high mortality of the
surgical shunt in cirrhotic animals (11). It has recently been
proposed a model that combines bile duct ligation with rats
fed with ammonia enriched diet, which have been found to
increase the ammonia levels in the blood and in the brain (8)
but the presence of behavioral changes in these animals, sug-
gesting the development of encephalopathy, has not been
found yet. Bile duct obstruction precludes testing biliary-
secreted drugs. Nevertheless, BDL model is easy to perform
and allow us to study ammonia metabolism in combination
with an inflammatory environment. In preliminary studies,
it has been shown that the reduction of ammonia with L-
ornithine phenylacetate (OP) is effective in BDL model.
Administration of OP results in increased conversion of glu-
tamate to glutamine by stimulation of glutamine synthase
activity in the muscle with the subsequent excretion of pheny-
lacetylglutamine in the urine, a reaction in which one mol-
ecule of ammonia is removed. Also, OP resulted in normal-
ization of glutaminase activity in the gut, indicating that OP
effectively restricts the production of in vivo ammonia in a
BDL model (9). These findings suggest developing approach-
es to target these enzymes to prevent ammonia release and
HE is a valid therapeutic strategy in BDL model. 
PORTOCAVAL SHUNT IN RATS
Many studies have been performed in rats with porta-
caval shunt (PCS) which have revealed some key knowl-
edge about the hyperammonemia in liver diseases (12) (Fig.
2). Initially, doubts arose about the adequacy of the model
to reproduce the symptoms in animals that could be equiv-
alent to human HE, but according to Bengsston and co-
workers (13-15) as well as other authors (16,17), changes
in behavior have been demonstrated in this model, espe-
cially in the areas of spontaneous activity in response to a
new environment and exploratory activity. Moreover, it
was found that these changes were reversible by applying
to the animal effective treatment for HE and, as mentioned
before, the model can be relevant for studying the HE.
Specifically, Conjeevaram and co-workers (18) demon-
strated that by adding neomycin to drinking water to rats
with PCS the motor activity was reduced after exposing
them to a new and dark environment, while Coy and col-
leagues also did so using a more sophisticated technique
by measuring disturbances of the circadian motor activity
(19). This group also demonstrated that operated rats shown
the same improvement when they were subjected to low
protein diet. It should be remembered, however, that the
mere fact of subjecting rats to a PCS cannot guarantee
the development of behavioral changes. Aspects such as the
surgical technique employed or the size of the stoma of the
microvascular anastomosis, which can have a significant
influence on the shunt pressure gradient; or the diet pro-
vided, the time from the intervention until the study is per-
formed in rats and even the age and weight of animals, may
affect the ability of researchers to detect significant changes
(20,21). Furthermore, it should be noted that hepatic neo-
vascularization may occur spontaneously developing
hepatopedal shunts, which are associated with recovery of
weight and decrease in HAM and sub-clinical HE in these
animals. 
Lee and Fisher (22) in 1961 and Bismuth in 1962 (23)
described a technique of direct portacaval anastomosis, reli-
able and reproducible, produced by vascular microsuture,
which even today continues in force by virtue of its good
results and reproducibility by different research groups.
However, because of the technical difficulty that is associ-
ated, there have been several attempts to simplify it further.
Funovics (24) in 1974 described a technique of anastomosis
mediated by using a Teflon tube that was intended to avoid
direct suturing and Jerkins (21) in 1988, one in which the
junction between the portal and cava veins was performed
using cyanoacrylate adhesive, with the intention to facilitate
handling of microsurgical vessel and therefore, the tech-
nique itself. However, further studies comparing these alter-
native types of shunts described by Bismuth and Lee con-
cluded that the pressure gradient between the portal and
cava systems were lower after surgical shunts. This would
suggest that the microsurgery anastomosis maintain a rate
of long-term viability higher than the alternative shunts,
which presented higher gradients because of their greater
tendency to be in the postoperative period. This would
explain the variability of results that had been previously
described using these alternative surgical techniques (20).
Fig. 1. Physiopathology of hepatic encephalopathy.
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Numata published in 1983 a modification of the tech-
nique that greatly simplifies and makes it easier and more
reproducible to minimize the operative time, a key issue in
the viability of the animal after the intervention (25). This
technique is based on a veno-venous microsurgical anas-
tomosis side-to-side between the porta and cava veins of
the rat, allowing a greater caliber of the shunt-side-end
anastomosis for Lee, Fisher and Bismuth, with a theoreti-
cally lower rate of long-term stenosis. Moreover, this tech-
nique allows its use as side-to-side anastomosis, depending
on how is left as following completion of the surgical shunt,
or end-side, if it is tied and cut at the proximal side of the
portal vein immediately after making anastomosis, enabling
application to experimental studies based on different pur-
poses (Fig. 3).
Since neither the psychometric tests nor clinical diag-
nosis for HE can be achieved in rats, we need to use alter-
native methods. Several authors have detailed some reflex
tests and evaluating responses to stimuli (26), difficult to
interpret, or computerized activity measurements (13,14)
or circadian rhythms (19), which represent a forward step
in this sense. According to Mullen (27), rats subjected to
PCS have an uncertain response of the spontaneous motor
activity, so even doing an adequate shunt; a large number
of animals is required to demonstrate significant behavioral
changes in operated animals compared to controls, despite
the use of more sophisticated methods of measurement.
Different systems have also been postulated to measure
evoked potentials (28) or the analysis of encephalographic
patterns (29), with low validation of data in HE animal
models.
Another crucial aspect is the technique of the shunt. A
wide sutured stoma, made with low vascular occlusion and
an expert surgeon are the basis of a lasting time porto-sys-
temic circuit and will be able to reproduce properly the
effects of HE, compared to techniques in which the shunt
Fig. 2. Four steps of portacaval shunt in rats. 
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is mediated by a “button” or made with cyanoacrylate, asso-
ciated with the reversibility of their effects (27). The com-
plexity of studies to assess encephalopathy in rats in terms
of their behavioral changes and lack of standardization, has
led us to limit the validation of the model to weight loss
and the study of biochemical changes that take place in the
hepatic encephalopathy syndrome.
A review article has been recently published in relation
to animal models for the study of HE (30) that stipulates
that PCS in rats would be an appropriate model for the type
B- EH, where there is a porto-systemic by-pass without
liver failure. However, as noted by Gandhi (31), “the PCS
is a model of liver atrophy for over 100 years”, referring
to the work of Hahn in the nineteenth century (32) and char-
acterized in great detail in Bismuth’s studies (33) during
the 60s of last century. In his early work was described as
“the appearance of the liver at laparotomy performed a few
days later to the rats subjected previously to PCS is pale,
and after sacrificing the animal and weigh it, there was a
significant reduction in its size.” This loss of liver size is
not parallel to the reduction in weight of the rat, because
the liver-weight / animal-weight ratio is also reduced (34).
In the liver under the microscope, a secondary atrophy is
observed that is not accompanied by changes in the com-
position in terms of the basic cellular components (water,
lipids, carbohydrates or proteins) or the hepatic architecture.
It seems to be related to hepatocyte atrophy, which begins
very early after surgery and may last for several months
during postoperative period (35). According to hepatocyte
function studies, several changes have been demonstrated
in these rats, as a decline in the production of bile salts
(about 40%), a loss of conjugation of bilirubin, an alteration
of the metabolism of biliary elimination of certain dyes,
such as indocyanine green –often used as a diagnostic
method for assessing the hepatic functional reserve before
hepatectomy in cirrhotic patients (36)–, alterations in
platelet aggregation and hepatic drug metabolism (37).
Hemodynamic and hormonal factors may be involved
in the genesis of this phenomenon. The PCS leads to a loss
of blood flow through the liver, despite the significant
increase, albeit not sufficient through the hepatic artery.
The main arguments for this hypothesis derived from exper-
imental observations where the atrophy is corrected almost
completely after a portacaval transposition or modification
of the portal vein (38). Moreover, the responsibility on the
phenomenon of loss in substances passing through the liver
with hepatotropic effect can be argued, mainly with pan-
creatic origin and that will affect liver regeneration. Among
these, insulin and glucagon have been the most extensively
studied (39). Bircher agrees “the highlights taking place in
this model are the porto-systemic shunt and loss of func-
tional liver parenchyma (40), implying that the model may
be considered appropriate to represent alterations in HE
type C” (which is associated with LC).
Neuron-anatomical lesions that appear in the encephalopa-
thy of liver disease are similar to those found in patients with
severe hyperammonemia by genetic defects of the enzymes
of the urea cycle. These findings were first described by Von
Hosslin and Alzheimer in 1912 (41) and in the case of liver
disease, these lesions are usually reversible after correction
of the increased level of ammonia. These cells show a very
pale enlarged nucleus, sometimes deformed, with a promi-
nent nucleolus and a marginal pattern of chromatin surround-
ed by a thin cytoplasmic layer, named as Alzheimer type II
cells (42). It is not uncommon in these patients to find a
spongiform degeneration of the deeper layers in the brain
cortex and the basal glia (43). There are no studies on dif-
ferent experimental models of HE where the neuro-anatom-
ical changes are described completely (44), although some
authors have demonstrated the presence of characteristic
Alzheimer cells type II after the completion of PCS in rats,
considered as the most characteristic neuron-anatomical alter-
ation of HE (45-48).
Pilbeam and co-workers published in 1983 (44) a study
on rat brain subjected to PCS and sacrificed at different
time points after surgery that questioned the presence of
Fig. 3. Plasma ammonia levels in simulated surgery, portacaval shunted and
bile duct ligation rats. 
Table I. Ten leap to perform portacaval shunt
1. To use inhalation anesthesia
2. Wide dissection of porta and cava veins
3. Avoiding vascular injury
4. Correct lateral clamp of both veins
5. Clamp time shorter than 15 minutes
6. Stomas should be 5 mm at least
7. Braided suture 7/0 with cylindrical needles
8. Hemostasis after declamping by soft compression
9. Ligation and portal vein section
10. Isolation of animals in separate cages to avoid injuries
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Alzheimer type II astrocytes in the operated animals. They
studied the brains of only 8 rats (2 animals with 2, 4, 16
and 30 weeks after surgery). They found that there were
not significant differences in ammonia plasma values
between operated and control animals (none of them the
mean value of plasma AM was even double that of the con-
trol group). In a study performed by our group where 24
rats were used, 8 and 16 under PCS in two control groups
of 8 each (control and sham), the values of ammonia plasma
of operated rats were found 4 to 5-fold higher than control
animals (49). Because of the details of the surgical tech-
nique, such as the extent of the stoma between the portal
and cava veins, often have important results regarding the
ability to reproduce the hyperammonemia in the liver
(20,21), we thought that perhaps there were some problems
in the surgical technique, leading to the low levels of plasma
ammonia in rats reported in the study, responsible for abnor-
mal brain histology.
PORTOCAVAL SHUNT WITH ADDITIONAL
HANDLING
The idea of reproducing the symptoms of a more severe
encephalopathy in rats (and occasionally in dogs) has been
the origin of the design of different manipulations in the
operated animals. A maneuver with potential utility is the
administration of ammonium resins to rats with PCS, which
apparently causes a reversible encephalopathy. Ammonium
managed by other means (for example i.v.) clearly produces
coma total, while still is not determined what this means
in human. Potentially, this coma is associated with induced
brain edema, even though there is no evidence on this issue.
Furthermore, there is no data demonstrating the reversibility
of the coma. Normal rats which were fed with ammonium
acetate developed hyperammonemia with a similar degree
to rats with PCS, and yet they were resistant to the time-
point administration of additional ammonia, but the rats
with PCS were, as mentioned above, in the opposite situ-
ation (50).
The superposition of an acute toxic hepatitis with
dimethyl-nitrosamide in dogs with PCD has been shown
to induce a severe HE (51). Alternative ways to induce HE
on animals with PCS included blood extraction or the intake
of high amounts of protein in the diet, which was effective
in dogs, but did not in rats. Partial hepatectomy has also
been used in some cases in PCS rats, or PCS to rats with
cirrhosis induced by tetrachloride carbon, but changes in
animal behavior were not reported.
Different works have been recently published using a
complete biliary ligation in rats with previous PCS, which
induced an acute or subacute cholestasis (11). This model
has not been fully characterized and has the added difficulty
of inducing a severe weight loss, probably caused by ano -
rexia or malabsorption.
In summary, the ideal HE animal model remains elusive.
Portacaval shunted rat remains as the gold standard method
for HE in animals. Easier to perform models like bile duct
ligation could be useful as complimentary model. The use-
fulness of adding methods require further studies. Porta-
caval shunt in CCL4-induced cirrhotic rats could be intrigu-
ing but extremely difficult with higher rat mortality.
Hyperammonia-based diet or thiacetamide-induced liver
failure could also be taken in mind when developing com-
bination models. Portacaval shunt is a good model for min-
imal hepatic encephalopathy and could be useful for the
development of new therapeutic agents. 
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